MassChallenge Startups Create Impact

2,458

Startups Accelerated

$6.2B

Funding Raised

$3B

Revenue Generated

157,000+

Jobs Created

Our startups

Be inspired. Search our startups.

Clear  
Combioxin
Combioxin

Combioxin develops disruptive life-saving solutions that revolutionize the treatment severe infections such as pneumonia, the most frequent and deadliest infectious disease. CAL02 has been ranked a “milestone” and “medical breakthrough”. CAL02 provides a totally new and eagerly awaited solution. This non-antibiotic drug is a universal toxin trap used on top of any antibiotic and regardless of resistance. CAL02 will transform standard of care and reduce cost of care for millions of patients.
Combioxin develops innovative life-saving solutions that revolutionize standard of care for patients with severe infections

Connect with Combioxin

2019

2019 Finalist Switzerland

Sub industry

Therapeutics (Pharma / Biotech)

Mission

MassChallenge strengthens the global innovation ecosystem by accelerating high-potential startups across all industries, from anywhere in the world.